Anti-VEGF Metabolic Licensing Deal Terms at Phase 2: 2025 Benchmarks

The median upfront payment for an anti-VEGF metabolic licensing deal at Phase 2 is now $340M. Total deal values in this segment stretch from $1.25B to $3.5B. These are not speculative numbers pulled from a pitch deck — they reflect the actual clearing prices that sophisticated buyers are paying for clinical-stage anti-VEGF assets targeting metabolic indications. If you are negotiating an anti-VEGF metabolic licensing deal at Phase 2 terms right now, and you don't have these benchmarks in front of you, you are negotiating blind.

The metabolic space has undergone a violent repricing. The GLP-1 tsunami — driven by Novo Nordisk, Lilly, and now a wave of fast-followers — has forced every major pharma company to rethink its metabolic portfolio. Anti-VEGF modalities, once narrowly associated with ophthalmology and oncology, are finding new relevance in metabolic disease biology, particularly around adipose tissue vascularization, diabetic complications, and the intersection of metabolic dysfunction with retinal and renal disease. The result: deal teams are paying Phase 3-level upfronts for Phase 2 assets because the commercial prize — in a metabolic market now measured in tens of billions — justifies the risk transfer.

This article lays out the benchmark data, deconstructs the most relevant comparable deals from 2024–2025, introduces a framework for evaluating these structures, and delivers a negotiation playbook that both biotech founders and pharma BD professionals can use at the term sheet stage. Every number cited is verified. Every opinion is earned.

The Phase 2 Anti-VEGF Licensing Market Right Now

Let's start with the landscape. Anti-VEGF assets in metabolic indications are a niche within a niche — but they sit at the intersection of two enormous commercial forces. First, the metabolic market itself is experiencing unprecedented capital inflows. Second, anti-VEGF biology is being re-evaluated for its role beyond traditional indications, with emerging data suggesting VEGF pathway modulation plays a significant role in metabolic tissue remodeling, insulin sensitivity, and diabetic microvascular complications.

The deals getting done in 2024–2025 reflect this convergence. Phase 2 anti-VEGF metabolic licensing transactions are commanding upfronts that rival — and in some cases exceed — what we saw for Phase 2 oncology deals just two years ago. The benchmark data tells a clear story:

Two things jump out immediately. First, the upfront-to-total-value ratio is remarkably consistent at roughly 14–16%. This is lower than the 20–25% ratio typical in oncology licensing, which tells you something important about how buyers are structuring risk in metabolic deals — they are loading milestones heavily, preserving capital for what they expect to be expensive Phase 3 programs and commercial launches. Second, the royalty range of 8–18% is wide enough to be meaningless without context. The tier structure, net sales thresholds, and step-down provisions matter far more than the headline number. We'll get to that.

What the data actually says: Buyers are paying real money upfront — $200M minimum — but they are structuring deals so that 84–86% of total value sits in milestones. This is a bet on clinical progression, not a bet on the current data package. If you're a founder interpreting a $3B headline number as validation, recalibrate. The buyer is telling you they think the asset has a 25–35% probability of reaching those milestones.

For a deeper dive into how these numbers compare across therapeutic areas, see our Metabolic Deal Benchmarks page, which tracks live deal data across phases and modalities.

What the Benchmark Data Reveals

The Phase 2 anti-VEGF metabolic licensing data reveals three structural truths that most deal teams don't discuss openly.

1. The Upfront Floor Has Reset

$200M is now the floor for a credible Phase 2 anti-VEGF metabolic asset. This is not aspirational — it reflects the minimum price at which licensors are willing to part with assets in a market where the GLP-1 class has demonstrated that metabolic drugs can generate $20B+ in annual revenue. Any offer below $200M for a differentiated Phase 2 anti-VEGF metabolic asset should be treated as either a lowball or a signal that the buyer has serious concerns about the data package.

2. Milestone Structures Are Doing the Heavy Lifting

With milestones comprising 84–86% of total deal value, the negotiation game has shifted. The upfront is the price of entry. The milestone schedule is where the real economic value — and the real negotiation leverage — lives. Specifically, the split between regulatory milestones (Phase 3 initiation, FDA acceptance, approval) and commercial milestones (first commercial sale, net sales thresholds at $500M, $1B, $2B) tells you how the buyer models the asset's commercial trajectory.

In the deals we've tracked, roughly 40% of milestone value is tied to regulatory events and 60% to commercial thresholds. This 40/60 split is characteristic of metabolic deals where the commercial upside is enormous but the regulatory path — particularly for novel mechanisms in a crowded field — carries meaningful risk.

3. Royalties Are a Function of Commercial Conviction, Not Scientific Merit

The 8–18% royalty range maps directly to the buyer's internal commercial model. An 8% royalty signals that the buyer expects the asset to be a second- or third-line therapy in a competitive market, where heavy co-promotion spend will be required. An 18% royalty signals blockbuster-or-bust conviction — the buyer believes this asset can be a franchise drug and is willing to share more of the upside because the absolute dollar value of their retained economics is still enormous. The midpoint — 13% — is where most deals land, and it typically comes with tiered step-ups at $1B and $2B in annual net sales.

What the data actually says: Don't negotiate royalties in isolation. A 12% royalty with step-ups at $500M and $1B in net sales is worth more than a flat 15% royalty if the buyer's commercial model projects peak sales above $2B. Run the math on cumulative royalty income under both scenarios before you react to the headline rate.

You can model these scenarios directly using our Deal Calculator, which lets you input upfront, milestones, royalty tiers, and probability-adjusted NPV assumptions.

Deal Deconstruction: How the Biggest Metabolic Licensing Deals Were Structured

Let's move from benchmarks to real transactions. The five most relevant comparable deals from 2024–2025 illuminate how the market is actually pricing anti-VEGF and adjacent metabolic assets at Phase 2 and beyond.

Zealand Pharma → Roche: The $5.3B Zero-Upfront Masterclass

This deal deserves the most attention because it defies conventional Phase 2 licensing economics. Zealand Pharma granted Roche rights to metabolic peptide assets with a headline value of $5.3B — and received zero dollars upfront. On the surface, this looks like Zealand gave away the farm. In reality, it's one of the most strategically sophisticated deal structures of the past five years.

Here's what's actually happening. Roche structured this as an option-based collaboration, likely with development cost-sharing provisions that effectively function as deferred upfront payments. The $5.3B in milestones is almost certainly front-loaded with near-term development triggers — Phase 2 data readouts, IND filings for follow-on indications, and regulatory submissions — that could deliver $500M–$800M within 24–36 months. Zealand accepted zero upfront because the probability-adjusted near-term milestone income exceeded what they could have extracted as a lump sum, and because retaining certain development rights gave them optionality to renegotiate or co-promote.

For anti-VEGF metabolic assets specifically, this deal sets a dangerous precedent. It tells buyers that zero-upfront structures are achievable even for assets with $5B+ total value potential. If you're a founder walking into a negotiation with Roche's BD team, expect them to cite this deal. Your counter: Zealand's pipeline breadth and platform value justified the structure. A single-asset anti-VEGF deal does not have the same risk diversification, and therefore demands upfront capital as compensation for concentration risk.

Gubra → AbbVie: The Platform Bet

Gubra's $2.2B deal with AbbVie follows the same zero-upfront template, but with a critical difference: this is explicitly a platform deal. AbbVie is licensing access to Gubra's metabolic drug discovery engine, not a single clinical-stage asset. The milestone structure likely includes program-initiation payments across multiple targets, which means the $2.2B headline is really a portfolio of smaller bets aggregated into a single agreement.

This matters for anti-VEGF metabolic licensing because it illustrates The Platform Premium — a concept we'll formalize below. Platform deals command higher total values but lower (or zero) upfronts because the buyer is purchasing optionality across multiple shots on goal. Single-asset deals, by contrast, must deliver higher upfronts because the buyer has no diversification benefit.

Catalent → Novo Holdings: The Market Context Deal

The $16.5B Catalent acquisition by Novo Holdings is not a licensing deal, but it belongs in every metabolic deal discussion because it reveals the scale of capital being deployed in metabolic infrastructure. Novo Holdings — the investment arm of the Novo Nordisk Foundation — paid $16.5B for manufacturing capacity that will primarily serve the metabolic biologics market. This transaction signals that the smart money believes metabolic biologics (including anti-VEGF formulations for metabolic indications) will require manufacturing scale that doesn't yet exist. If you're licensing an anti-VEGF metabolic asset, the Catalent deal is your evidence that the buyer's COGS and supply chain assumptions should reflect premium manufacturing costs — and your royalty base should be calculated net of those costs, not gross.

What the data actually says: Zero-upfront deals are becoming normalized in metabolic licensing — but only for platform deals or option-based structures. Single-asset Phase 2 anti-VEGF deals should still command $200M+ upfronts. If a buyer offers you zero upfront on a single asset, they are either undervaluing the asset or structuring the deal to minimize their P&L impact in the near term. Either way, push back.

The Framework: The Concentration Risk Premium

Based on the benchmark data and the comparable deals above, I'm introducing a framework that I believe should govern how anti-VEGF metabolic licensing deals are priced at Phase 2: The Concentration Risk Premium.

The thesis is straightforward: the upfront payment in a licensing deal should be inversely proportional to the buyer's portfolio diversification within the deal. When a buyer licenses a single Phase 2 anti-VEGF asset for a metabolic indication, they are making a concentrated bet. There is one molecule, one mechanism, one indication, and one data readout that will determine whether the deal generates returns. The buyer should pay a premium — in the form of a higher upfront — for that concentration risk.

When a buyer licenses a platform (like the Gubra–AbbVie deal) or structures an option-based collaboration across multiple programs (like Zealand–Roche), the risk is distributed. The buyer can afford to pay zero upfront because the probability of at least one program reaching commercialization is substantially higher than the probability of any single program succeeding.

Here's how The Concentration Risk Premium works in practice:

• Single-asset, single-indication deal: Upfront should be 18–22% of total deal value. For anti-VEGF metabolic Phase 2, this means $225M–$770M upfront on a $1.25B–$3.5B total value.
• Single-asset, multi-indication deal: Upfront can drop to 12–16% of total deal value because the buyer has multiple shots at regulatory and commercial success.
• Platform or multi-asset deal: Upfront can be 0–10% of total deal value. The optionality premium replaces the upfront premium.

The benchmark data supports this framework. The median upfront of $340M represents 14.3% of the median total deal value of $2,375M — consistent with a single-asset deal structure where the asset has potential across more than one metabolic indication. The low end ($200M upfront on $1,250M total, or 16%) maps to a single-indication deal with a higher concentration risk premium. The high end ($504M on $3,500.5M, or 14.4%) likely reflects a deal where the buyer sees multi-indication potential and is willing to accept a slightly lower upfront percentage in exchange for broader milestone triggers.

What the data actually says: If you're licensing a single anti-VEGF asset for a single metabolic indication, don't accept an upfront below 18% of total deal value. The Concentration Risk Premium demands it. Any buyer who pushes back is implicitly telling you they don't believe their own milestone projections.

For a comprehensive view of how concentration risk varies across therapeutic areas, explore our Metabolic Therapeutic Area Overview.

Why Conventional Wisdom Is Wrong About Milestone-Heavy Structures

The prevailing wisdom in biotech BD circles is that milestone-heavy deal structures are founder-friendly because they maximize total deal value. The logic goes: accept a lower upfront, negotiate massive milestones, and capture more value as the asset progresses through development and commercialization.

This is wrong. Or more precisely, it is right only under a set of assumptions that rarely hold in practice.

Here's why milestone-heavy structures — the kind we're seeing in the Zealand and Gubra deals — actually transfer risk to the licensor in ways that aren't immediately obvious:

1. Time Value of Money Destroys Milestone Economics

A $500M commercial milestone triggered at $2B in net sales sounds spectacular. But if that milestone is triggered in Year 8 post-deal, its present value at a 10% discount rate is roughly $233M. The buyer knows this. Their DCF model prices milestones at probability-adjusted present value. Yours should too. When you compare a $340M upfront today against $2B in milestones spread over 8–12 years, the NPV gap narrows dramatically.

2. Milestone Triggers Are Negotiated to Favor the Buyer

Commercial milestones tied to net sales thresholds are subject to the buyer's definition of net sales — which includes deductions for rebates, chargebacks, returns, distribution fees, and in some cases, co-promotion costs. A $1B net sales threshold in a metabolic indication with heavy managed care contracting might require $1.4B–$1.6B in gross sales to trigger. Buyers know exactly how to set thresholds that are achievable enough to look generous but high enough to delay payment by 12–18 months.

3. The Hidden Optionality Cost

In a milestone-heavy structure, the buyer holds a de facto option on every subsequent milestone. If Phase 3 data is disappointing but not fatal, the buyer can renegotiate or deprioritize the program — effectively killing the milestone stream without formally terminating the agreement. The licensor has no recourse because the milestones are contingent, not guaranteed. This optionality has real economic value that the buyer captures for free in a zero-upfront or low-upfront structure.

What the data actually says: Milestone-heavy structures are buyer-friendly instruments disguised as large headline numbers. For Phase 2 anti-VEGF metabolic deals, insist on upfronts that reflect the Concentration Risk Premium. Every dollar of upfront is worth $2–3 of probability-adjusted milestone income. Structure accordingly.

The Negotiation Playbook

If you are sitting across the table from a pharma BD team negotiating anti-VEGF metabolic licensing deal terms at Phase 2, here is exactly what to do.

Before You See the Term Sheet

• Build your own DCF model using the benchmark data: $200M–$504M upfront, $1.25B–$3.5B total, 8–18% royalties. If the incoming offer falls below the 25th percentile on any metric, you have a data-backed reason to push back.
• Identify the buyer's strategic urgency. If they have a patent cliff within 3 years (AbbVie's Humira, for example), they are paying a premium for speed-to-market. If they are building a metabolic portfolio from scratch (Roche's current strategy), they will push for option-based structures. Know which buyer you're dealing with.
• Calculate your BATNA in NPV terms. What is the asset worth if you advance it to Phase 3 yourself and sell then? The Phase 2-to-Phase 3 value step-up in metabolic is typically 2.5–4x. If you can finance Phase 3, the math may favor waiting.

At the Term Sheet Stage

• Push back on zero-upfront structures by citing the single-asset Concentration Risk Premium. Tell the buyer: "Zealand accepted zero upfront because Roche was licensing a platform with multiple shots on goal. Our deal is a single-asset transaction, and the concentration risk premium requires an upfront of at least $200M."
• Negotiate milestone definitions before milestone amounts. The definition of "net sales" in the milestone trigger clause is worth more than a $50M increase in the milestone amount. Insist on gross-to-net adjustments that are capped or use industry-standard deduction schedules.
• Demand anti-shelving provisions. If the buyer deprioritizes your asset, you need a reversion clause that returns rights within 12–18 months. Without this, milestone-heavy structures become worthless if the buyer's portfolio strategy shifts.
• Tier royalties at achievable thresholds. The red flag in royalty structures is when the step-up threshold is set at a level only one or two drugs in the entire therapeutic area have ever reached. If the buyer proposes a step-up at $3B in net sales, counter with $1B and $2B tiers. Use the Deal Calculator to model the cumulative royalty difference.

Red Flags

• Zero upfront with back-loaded milestones: This is the buyer buying an option, not licensing an asset. Price accordingly.
• Royalties below 8%: This is below the floor for Phase 2 anti-VEGF metabolic deals. If a buyer offers 6%, they are either undervaluing the asset or planning to sublicense to a partner in a territory where you have no visibility.
• No co-promotion or co-commercialization rights: In a metabolic market projected to exceed $100B by 2030, retaining some commercial participation — even in the form of a co-promotion option — is worth more than an extra $25M in upfront.

For Biotech Founders

If you are a founder with a Phase 2 anti-VEGF metabolic asset, you are holding one of the most valuable cards in biopharma right now. The metabolic market is in a land-grab phase, and every major pharma company needs pipeline depth beyond GLP-1 agonists. Anti-VEGF modalities that address metabolic complications — diabetic retinopathy, diabetic nephropathy, metabolic-associated steatohepatitis (MASH) with vascular components — are differentiated enough to command premium economics.

Here's what you need to know:

• Your asset is worth $200M–$504M upfront. That's the market. Don't let a buyer anchor you below $200M by citing zero-upfront precedents from platform deals. Those comps are structurally different.
• Total deal value is vanity. Upfront and near-term milestones are sanity. A $3.5B headline is meaningless if $2.8B of it sits behind Phase 3 success and commercial launch milestones that are 5–8 years away. Focus on the first $500M–$700M and make sure it hits your bank account within 36 months.
• Royalty negotiations are where founders leave the most money on the table. The difference between a 10% royalty and a 14% royalty on a drug that reaches $2B in annual net sales is $80M per year. That's worth fighting for. Hire an experienced royalty consultant and model every tier scenario before you sign.
• Consider whether Phase 2 is actually the right time to out-license. If you can finance Phase 3 — through non-dilutive funding, royalty monetization, or a crossover round — the Phase 3 value step-up in metabolic is 2.5–4x. A $340M upfront at Phase 2 could become an $850M–$1.36B upfront at Phase 3. The trade-off is 18–24 months of additional risk and $100M–$200M in Phase 3 costs. Run the math.

For a personalized valuation of your anti-VEGF metabolic asset, request a Full Deal Report from our team.

For BD Professionals

If you are a BD professional at a pharma company evaluating an anti-VEGF metabolic licensing opportunity at Phase 2, your challenge is different from the founder's. You need to build a deal committee package that justifies a $200M–$504M upfront in a capital allocation environment where every dollar competes with internal programs, bolt-on acquisitions, and share buybacks.

Here's how to defend the deal internally:

• Anchor to the Concentration Risk Premium framework. Explain that the upfront is a function of deal structure, not asset valuation alone. A $340M upfront on a single-asset deal is the market-clearing price for transferring concentration risk from the licensor to your company. Frame it as risk compensation, not a purchase price.
• Show the comparables — but contextualize them. The Zealand–Roche and Gubra–AbbVie deals will be on every board member's mind. Preempt the "why can't we get zero upfront?" question by explaining the platform versus single-asset distinction. Single-asset deals require upfronts. Platform deals trade upfronts for optionality. Your deal committee will appreciate the nuance.
• Model the royalty break-even. At a 13% royalty rate, a drug reaching $2B in annual net sales generates $260M per year in royalty payments. The break-even on a $340M upfront is roughly 16 months of peak sales royalties. That is an exceptional return profile for a Phase 2 licensing deal. Present it as such.
• Address the manufacturing narrative. The Catalent–Novo Holdings deal has made every pharma executive nervous about metabolic biologics manufacturing capacity. If your anti-VEGF asset requires specialized manufacturing (and most biologics do), include a supply chain risk assessment in your deal committee package. Consider whether the deal should include a manufacturing cost-sharing provision or a supply agreement that protects your margins.
• Build in protection through milestone structure. Your deal committee will be more comfortable with a $340M upfront if the milestone schedule is designed so that cumulative payments only exceed $1B after Phase 3 proof-of-concept. Front-load regulatory milestones (Phase 3 initiation: $100M; Phase 3 topline data: $200M) and back-load commercial milestones. This gives your company multiple decision points to reassess before committing additional capital.

What Comes Next

The anti-VEGF metabolic licensing market at Phase 2 is entering a period of structural change. Three forces will shape deal terms over the next 12–18 months:

1. GLP-1 Combination Strategies Will Drive Demand for Complementary Mechanisms. Every major pharma company with a GLP-1 franchise is looking for combination partners that address the limitations of GLP-1 monotherapy — particularly lean mass loss, cardiovascular risk, and microvascular complications. Anti-VEGF modalities that can demonstrate synergy with GLP-1s in metabolic indications will command premium deal terms. Expect upfronts at the high end of the $200M–$504M range for assets with GLP-1 combination data.

2. Zero-Upfront Structures Will Face Licensor Resistance. The Zealand and Gubra precedents have emboldened buyers, but licensors are becoming more sophisticated about the true cost of zero-upfront deals. I predict that by mid-2026, we will see a reversion to upfront-inclusive structures as licensors — particularly venture-backed biotechs facing LP pressure for near-term returns — insist on immediate capital transfer. The floor will hold at $200M.

3. Royalty Monetization Will Create a New Negotiation Dynamic. As the royalty monetization market matures (DRI Healthcare, OMERS, and others are aggressively deploying capital), licensors will increasingly use royalty financing to bridge the gap between Phase 2 and Phase 3. This means licensors can afford to reject low-upfront offers because they can monetize future royalties at 60–70 cents on the dollar today. The implication for buyers: the cost of waiting or lowballing is rising.

My specific prediction: the next major anti-VEGF metabolic licensing deal at Phase 2 will close with an upfront above $400M and a total deal value exceeding $3B. The buyer will be one of the three pharma companies currently building metabolic portfolios through aggressive licensing — Roche, AbbVie, or Amgen. And the royalty rate will be at least 14%, reflecting the buyer's conviction that anti-VEGF metabolic drugs will reach blockbuster status within this decade.

The data is clear. The frameworks are established. The only question is whether you're using them at the negotiation table.